Will A CV Warning On Meridia Alter FDA Views On Obesity Drugs?
This article was originally published in The Pink Sheet Daily
Executive Summary
The diet pill was not approved or recommended for use in about 90 percent of patients in the trial that triggers the warning, Abbott says.
You may also be interested in...
Eisai's High Dose Aricept Beats Expectations, But Lack Of Solutions Plague Mid-term Forecast
TOKYO - A higher-dose Aricept anti-Alzheimer treatment U.S. FDA approved this summer is set to be a core revenue contributor for Eisai through its business year ending next March and on, and if its endotoxin antagonist eritoran for severe sepsis is approved, the growth momentum could continue through 2012, according to Eisai and analysts
Vivus' Qnexa Gets "Complete Response" Letter From FDA
FDA wants more data on risk of birth defects, cardiovascular effects, but doesn't ask for new clinical trials - at least for now.
Vivus' Qnexa Gets "Complete Response" Letter From FDA
FDA wants more data on risk of birth defects, cardiovascular effects, but doesn't ask for new clinical trials - at least for now.